Skip to content

Coping and Adjusting to Living With Multiple Sclerosis

Efficacy of a Psychosocial Intervention to Improve Ability to Cope With Uncertainty in MS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04300816
Acronym
CALMS
Enrollment
242
Registered
2020-03-09
Start date
2019-10-30
Completion date
2022-11-11
Last updated
2023-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The purpose of this project is to test a brief, telephone-based psychological intervention, CBT-UT, to improve the ability to tolerate uncertainty-and thereby to reduce distress-in people with a recent diagnosis of Multiple Sclerosis (MS). There are three treatment arms for this study. Participants will receive either (1) CBT for Uncertainty Tolerance, (2) Traditional CBT, or (3) treatment as usual.

Detailed description

Despite substantial improvements in diagnosis and treatment, Multiple Sclerosis (MS) remains an unpredictable disease. Although some physicians can make some predictions about expected progression, the variable course of exacerbations makes it almost impossible to predict how MS will develop or affect function over time. As a result, people with MS must learn to live in a state of chronic uncertainty and the ability to tolerate and cope with this kind of uncertainty is central to quality of life with MS. Individuals who require certainty about the future and are not able to tolerate ambiguity are said to be high in a personality trait known as intolerance of uncertainty (IU). There is a significant gap in MS clinical intervention that necessitates attention. An intervention that specifically targets IU, is developed for people recently diagnosed with MS, and can be provided remotely via telehealth can make a significant impact for this population. Study aims include: (1) to determine the efficacy of CBT-UT relative to traditional cognitive behavioral therapy (tCBT) or treatment as usual (TAU) in people diagnosed with MS in the past 3 years; and (2) To increase our understanding of the mechanisms underlying the intervention effects.

Interventions

BEHAVIORALCBT for Uncertainty Tolerance

Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis.

BEHAVIORALTraditional CBT

Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.

Sponsors

National Multiple Sclerosis Society
CollaboratorOTHER
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Research manager will be blinded for this trial. Research coordinator and investigator will not.

Intervention model description

3- arm randomized clinical trial. Arms: (1) CBT for uncertainty tolerance, (2) traditional CBT, (3) treatment as usual

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults over 18 years of age * MS diagnosis using revised McDonald Criteria * Able to read, speak, and understand English * At least mild psychological distress evidenced by (1) a score of 20 or higher on the Kessler Psychological Distress Scale OR (2) a score greater than or equal to 5 on the Perceived Stress Scale.

Exclusion criteria

* Severe cognitive impairment defined as one or more error on the Six-Item Screener * Psychiatric condition or symptoms that would interfere with participation, specifically (1) current, active suicidal ideation with current intent to harm oneself, (2) current psychosis, or (3) current mania.

Design outcomes

Primary

MeasureTime frameDescription
Questionnaire: Level of MS Acceptance as measured by the Acceptance of Chronic Health Conditions, MS Version Questionnaire.6 MonthsThis is a self-reported measure of perceived MS Acceptance. Greater scores represent greater MS Acceptance.
Questionnaire: Level of anxiety as measured by the Global Anxiety Disorder-7 scale (GAD-7).6 MonthsThis is a self-reported measure of perceived anxiety. Greater scores represent greater levels of anxiety.
Questionnaire: Level of depression as measured by the Patient Health Questionnaire (PHQ-9).6 MonthsThis is a self-reported measure of perceived depression. Greater scores represent greater levels of depression.

Secondary

MeasureTime frameDescription
Demographic: MS Progression Type. Measured by self-reported type of MS.BaselineThis is a self-reported demographic question. Options include: Relapsing-Remitting, Primary-Progressive, Secondary-Progressive, Progressive-Relapsing, and Don't Know.
Demographic: Biological Sex. Measured by self-report.BaselineThis is a self-reported demographic question. Options include: Male, Female, Transgender, and If not listed explain.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026